Eyenovia (NASDAQ:EYEN) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Share on StockTwits

Eyenovia (NASDAQ:EYEN) issued its quarterly earnings data on Monday. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.03, Bloomberg Earnings reports.

Shares of EYEN opened at $3.34 on Wednesday. Eyenovia has a 12 month low of $2.40 and a 12 month high of $6.98. The stock’s fifty day simple moving average is $3.47. The firm has a market capitalization of $55.24 million, a PE ratio of -1.84 and a beta of 1.11.

Several equities research analysts have recently issued reports on the stock. HC Wainwright set a $14.00 price objective on shares of Eyenovia and gave the stock a “buy” rating in a research report on Wednesday, June 5th. Zacks Investment Research raised shares of Eyenovia from a “sell” rating to a “hold” rating in a research report on Tuesday, June 25th. ValuEngine raised shares of Eyenovia from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Oppenheimer assumed coverage on shares of Eyenovia in a research report on Wednesday, April 24th. They set an “outperform” rating and a $9.00 price objective for the company.

In other Eyenovia news, CEO Tsontcho Ianchulev bought 233,813 shares of Eyenovia stock in a transaction that occurred on Thursday, July 11th. The stock was acquired at an average price of $2.78 per share, for a total transaction of $650,000.14. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Curt H. Labelle bought 17,985 shares of Eyenovia stock in a transaction that occurred on Thursday, July 11th. The shares were acquired at an average price of $2.78 per share, with a total value of $49,998.30. The disclosure for this purchase can be found here. Corporate insiders own 43.10% of the company’s stock.

An institutional investor recently bought a new position in Eyenovia stock. Bank of New York Mellon Corp bought a new position in shares of Eyenovia Inc (NASDAQ:EYEN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,529 shares of the company’s stock, valued at approximately $36,000. Bank of New York Mellon Corp owned about 0.11% of Eyenovia at the end of the most recent quarter. 7.88% of the stock is currently owned by institutional investors.

Eyenovia Company Profile

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

See Also: What is net income?

Earnings History for Eyenovia (NASDAQ:EYEN)

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Spotify  Holdings Lifted by Prime Capital Investment Advisors LLC
Spotify Holdings Lifted by Prime Capital Investment Advisors LLC
Inogen Inc  Expected to Announce Earnings of $0.23 Per Share
Inogen Inc Expected to Announce Earnings of $0.23 Per Share
AMN Healthcare Services, Inc.  Given Consensus Rating of “Buy” by Brokerages
AMN Healthcare Services, Inc. Given Consensus Rating of “Buy” by Brokerages
$4.09 Billion in Sales Expected for General Mills, Inc.  This Quarter
$4.09 Billion in Sales Expected for General Mills, Inc. This Quarter
Endeavour Silver Corp  Receives $2.75 Consensus Target Price from Brokerages
Endeavour Silver Corp Receives $2.75 Consensus Target Price from Brokerages
Brokerages Set Alamos Gold Inc  Target Price at $6.77
Brokerages Set Alamos Gold Inc Target Price at $6.77


© 2006-2019 Ticker Report